Akari Therapeutics, Plc Derivative Asset, Current
Akari Therapeutics, Plc (AKTX) had Derivative Asset, Current of $0 as of 2023-12-31, per its 8-K filed 2024-09-06.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DerivativeAssetsCurrent · last filed 2024-09-06
- 2023-12-31: Derivative Asset, Current $0.00.
- 2022-12-31: Derivative Asset, Current $13.00K.
| Period end | Derivative Asset, Current |
|---|---|
| 2023-12-31 | $0.00 8-K · filed 2024-09-06 |
| 2022-12-31 | $13.00K 8-K · filed 2024-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |